Management of helicobacter pylori infection

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 8, 2010, Pages 887-892

  Costa, Francesco ^a   Delios, Mario M ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

antibacterials; antibiotics; diagnostic test; endoscopy; gastric cancer; gastric lymphoma; Helicobacter pylori; peptic ulcer; urea breath test; vaccine

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BISMUTH; CLARITHROMYCIN; FURAZOLIDONE; HELIDAC; LEVOFLOXACIN; METRONIDAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BONE MARROW TOXICITY; DIARRHEA; DRUG MEGADOSE; ENDOSCOPY; EYE DISEASE; FECES ANALYSIS; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; NAUSEA; NON INVASIVE MEASUREMENT; PEPTIC ULCER; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SEROLOGY; STOMACH CANCER; STOMACH LYMPHOMA; TASTE DISORDER; UREA BREATH TEST; VOMITING;

ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; HEALTH PLANNING GUIDELINES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS;

EID: 77955579968     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.75     Document Type: Review

References (41)

1. Warren JR, Marshall BJ. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulcer ulceration. Lancet 1, 1273-1275 (1983).
2. Wotherspoon AC, Doglioni C, Diss TC et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342, 575-577 (1993).
3. DElios MM, Appelmelk BJ, Amedei A et al. Gastric autoimmunity: the role of Helicobacter pylori and molecular mimicry. Trends Mol. Med. 7, 316-323 (2004).
4. No authors listed. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr. Eval. Carcinog. Risks Hum. 61, 1-241 (1994).
5. Ogura K, Hirata Y, Yanai A et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J. Clin. Gastroenterol. 42, 279-283 (2008).
6. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J. Clin. Invest. 119, 2475-2487 (2009).
7. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin. Microbiol. Rev. 20, 280-322 (2007).
8. Bayerdorffer E, Oertel H, Lehn N et al. Topographic association between active gastritis and Campylobacter pylori colonisation. J. Clin. Pathol. 42, 834-839 (1989). (Pubitemid 19190754)
9. Trebesius K, Panthel K, Strobel S et al. Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. Gut 46, 608-614 (2000).
10. Zullo AA, Hassan C, Lorenzetti R, Winn S, Morini S. A clinical practice viewpoint: to culture or not to culture Helicobacter pylori? Dig. Dis. Liver Dis. 35, 357-361 (2003).
11. Malfertheiner P, Megraud F, OMorain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 56, 772-781 (2007). (Pubitemid 46854190)
12. Oleastro M, Menard A, Santos A et al. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J. Clin. Microbiol. 41, 397-402 (2003).
13. Glocker E, Kist M. Rapid detection of point mutations in the gyrA gene of Helicobacter pylori conferring resistance to ciprofloxacin by a fluorescence resonance energy transfer-based real-time PCR approach. J. Clin. Microbiol. 42, 2241-2246 (2004).
14. Ribeiro ML, Gerrits MM, Benvengo YH et al. Detection of high-level tetracycline resistance in clinical isolates of Helicobacter pylori using PCR-RFLP. FEMS Immunol. Med. Microbiol. 40, 57-61 (2004).
15. DElios MM, Amedei A, Benagiano M, Azzurri A, Del Prete G. Usefulness of 13C-urea breath test in the diagnosis of gastric Helicobacter pylori infection. Int. J. Immunopathol. Pharmacol. 13, 27-30 (2000).
16. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment. Pharmacol. Ther. 20, 1001-1017 (2004).
17. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 9, 347-368 (2004).
18. Hoang TT, Wheeldon TU, Bengtsson C, Phung DC, Sorberg M, Granstrom M. Enzyme-linked immunosorbent assay for Helicobacter pylori needs adjustment for the population investigated. J. Clin Microbiol. 2, 627-630 (2004).
19. Obata Y, Kikuchi S, Miwa H, Yagyu K, Lin Y, Ogihara A. Diagnostic accuracy of serological kits for Helicobacter pylori infection with the same assay system but different antigens in a Japanese patient population. J. Med. Microbiol. 52, 889-892 (2003).
20. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 359, 14-22 (2002).
21. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N. Engl. J. Med. 344, 967-973 (2001).
22. Chan FK, To KF, Wu JC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 359, 9-13 (2002).
23. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAID users. Aliment. Pharmacol. Ther. 21, 1411-1418 (2005).
24. DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am. J. Gastroenterol. 100(2), 453-459 (2005).
25. Annibale B, Marignani M, Monarca B et al. Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis. Ann. Intern. Med. 131, 668-672 (1999).
26. Gasbarrini A, Franceschi F, Tartaglione R et al. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 352, 878 (1998). (Pubitemid 28416725)
27. Tsutsumi Y, Kanamori H, Yamato H et al. Randomized study of H. pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann. Hematol. 84, 807-811 (2005).
28. Fuccio L, Laterza L, Zagari RM, Cennamo V, Grilli D, Bazzoli F. Treatment of Helicobacter pylori infection. Br. Med. J. 337, a1454 (2008).
29. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 56, 1502 (2007).
30. Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol. 7, 145-148 (2009).
31. Francois F, Blaser MJ. Improving Helicobacter pylori eradication regimens. Ann. Intern. Med. 44, 140-141 (2006).
32. Zullo A, De Francesco V, Hassan C, Morini S, Vaira D. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 56, 1353-1357 (2007). (Pubitemid 47517826)
33. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am. J. Gastroenterol. 101, 488-496 (2006).
34. Lamouliatte H, Megraud F, Delchier JC et al. Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies. Aliment. Pharmacol. Ther. 18, 791-797 (2003).
35. Laine L, Hunt R, El-Zimaity H, Nguyen B, Osato M, Spenard J. Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am. J. Gastroenterol. 98, 562-567 (2003).
36. OMorain C, Borody T, Farley A et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment. Pharmacol. Ther. 17, 415-420 (2003).
37. Abbas Z, Yakoob J, Abid S et al. Furazolidone, co-amoxiclav, colloidal bismuth subcitrate, and esomeprazole for patients who failed to eradicate Helicobacter pylori with triple therapy. Dig. Dis. Sci. 54, 1953-1957 (2009).
38. Cheng H, Hu FL. Furazolidone, amoxicillin, bismuth and rabeprazole quadruple rescue therapy for the eradication of Helicobacter pylori. World J. Gastroenterol. 15, 860-864 (2009).
39. Borody TJ, Pang G, Wettstein AR et al. Efficacy and safety of rifabutin-containing rescue therapy for resistant Helicobacter pylori infection. Aliment. Pharmacol. Ther. 23, 481-488 (2006).
40. Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterology 135, 787-795 (2008).
41. Rupnow MF, Chang AH, Shacter RD, Owens DK, Parsonnet J. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States. J. Infect. Dis. 200, 1311-1317 (2009).